Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents

Pediatric Blood and Cancer

Volumn 54, Issue 3, 2010, Pages 361-368

  Vangipuram, Sharada D ^a   Wang, Zhihong J ^a   Lyman, William D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cells; Drug resistance; Neuroblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CD133 ANTIGEN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; THERAPY RESISTANCE; WESTERN BLOTTING;

ANTIGENS, CD; BLOTTING, WESTERN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GLYCOPROTEINS; HUMANS; NEOPLASTIC STEM CELLS; NEUROBLASTOMA; PEPTIDES; SARCOMA, EWING'S;

EID: 76749122743     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22351     Document Type: Article

References (52)

1. Gil J, Stembalska A, Pesz KA, et al. Cancer stem cells: The theory and perspectives in cancer therapy. J Appl Genet 2008;49:193-199.
2. Besancon R, Valsesia-Wittmann S, Puisieux A, et al. Cancer stem cells: The emerging challenge of drug targeting. Curr Med Chem 2009;16:394-416.
3. Cho RW, Clarke MF. Recent advances in cancer stem cells. Curr Opin Genet Dev 2008;18:48-53.
4. Costa FF, Le Blanc K, Brodin B. Concise review: Cancer/testis antigens, stem cells, and cancer. Stem Cells 2007;25:707-711.
5. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
6. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988.
8. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
9. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007;104:10158-10163.
10. Walton JD, Kattan DR, Thomas SK, et al. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 2004;6:838-845.
11. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells in human tumor cells: Implications for tumor biology and therapy. Cell Cycle 2005;4:203-205.
12. MahllerYY,Williams JP, BairdWH,et al. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE 2009;4:e4235.
13. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007;67:4010-4015.
14. Bernstein ML, Leclerc JM, Bunin G, et al. A population-based study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol 1992;10:323-329.
15. Barami K, Grever WE, Diaz FG, et al. An efficient method for the culturing and generation of neurons and astrocytes from second trimester human central nervous system tissue. Neurol Res 2001;23:321-326.
16. Wang Z, Xu J, Zhou JY, et al. Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Res 2006;66:8870-8877.
17. Ozgen U, Savasan S, Buck S, et al. Comparison of DiOC(6)(3) uptake and annexin V labeling for quantification of apoptosis in leukemia cells and non-malignant T lymphocytes from children. Cytometry 2000;42:74-78.
18. Komuro H, Saihara R, Shinya M, et al. Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines. J Pediatr Surg 2007;42:2040-2045.
19. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004;101:14228-14233.
20. Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 2000;97: 14720-14725.
21. LaQuaglia MP, Kopp EB, Spengler BA, et al. Multidrug resistance in human neuroblastoma cells. J Pediatr Surg 1991;26:1107-1112.
22. Kennedy KA. Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des 1987;2:181-194.
23. Kushner BH, Vogel R, Hajdu SI, et al. Metastatic neuroblastoma and testicular involvement. Cancer 1985;56:1730-1732.
24. Keshelava N, Seeger RC, Groshen S, et al. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998;58:5396-5405.
25. Todaro M,D'Asaro M, Caccamo N, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009;182:7287-7296.
26. Shervington A, Lu C, Patel R, et al. Telomerase downregulation in cancer brain stem cell. Mol Cell Biochem 2009.
27. Nakai E, Park K, Yawata T, et al. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Investigation 2009;27:901-908.
28. Mathew M, Verma RS. Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009;100:1359-1365.
29. Johannessen TC, Wang J, Skaftnesmo KO, et al. Highly infiltrative brain tumours showreduced chemosensitivity associated with a stem cell-like phenotype. Neuropathol Applied Neurobiol 2008;35:380-393.
30. RobsonH,MeyerS, ShaletSM, et al. Platinumagents in the treatment of osteosarcoma: Efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines. Med Pediatr Oncol 2002;39:573-580.
31. Ritzmo C, Soderhall S, Karlen J, et al. Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient. Pediatr Hematol Oncol 2007;24:437-445.
32. Pein F, Pinkerton R, Berthaud P, et al. Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours. Eur J Cancer 2007; 43:2074-2081.
33. Ekhart C, de Jonge ME, Huitema AD, et al. Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res 2006;12:6502-6508.
34. Busse D, Wurthwein G, Hinske C, et al. Pharmacokinetics of intravenous etoposide in patients with breast cancer: Influence of dose escalation and cyclophosphamide and doxorubicin coadministration. Naunyn Schmiedebergs Arch Pharmacol 2002;366:218-225.
35. Sargent JM. The use of the MTT assay to study drug resistance in fresh tumour samples. Recent Results Cancer Res 2003;161:13-25.
36. Hayon T, Dvilansky A, Shpilberg O, et al. Appraisal of the MTTbased assay as a useful tool for predicting drug chemosensitivity in leukemia. Leuk Lymphoma 2003;44:1957-1962.
37. Kratzke RA, Kramer BS. Evaluation of in vitro chemosensitivity using human lung cancer cell lines. J Cell Biochem Suppl 1996;24:160-164.
38. Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, et al. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy 2009;11:26-34.
39. Clement V, Dutoit V, Marino D, et al. Limits of CD133 as a marker of glioma self-renewing cells. Int J Cancer 2009;125:244-248.
40. Liu J, Chao B. MRI-based visualization of iron-labeled CD133+ human endothelial progenitor cells. Biol Trace Elem Res 2008; 126:83-91.
41. Drewa T, Wolski Z, Pokrywka L, et al. Progenitor cells are responsible for formation of human prostate epithelium primary cultures. Exp Oncol 2008;30:148-152.
42. Jaatinen T, Laine J. Isolation of hematopoietic stem cells from human cord blood. Curr Protoc Stem Cell Biol 2007; Chapter 2: Unit 2A.2.
43. Drewa T, Styczynski J. Progenitor cells are responsible for formation primary epithelial cultures in the prostate epithelial model. Int Urol Nephrol 2007;39:851-857.
44. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
45. Shervington A, Lu C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest 2008;26:535-542.
46. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007;26:3100-3112.
47. Thornton TM, Rincon M. Non-classical p38 map kinase functions: Cell cycle checkpoints and survival. Int J Biol Sci 2009;5: 44-51.
48. Ohmichi M, Hayakawa J, Tasaka K, et al. Mechanisms of platinum drug resistance. Trends Pharmacol Sci 2005;26:113-116.
49. Hui L, Bakiri L, Stepniak E, et al. p38alpha: A suppressor of cell proliferation and tumorigenesis. Cell Cycle 2007;6:2429-2433.
50. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2009;16:368-377.
51. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-869.
52. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007;26:3203-3213.